Appelbaum Kevin J's Form 4 filing
Better Therapeutics, Inc. (BTTX) · filed Apr 4, 2022
- Accession no.
- 0000899243-22-013342
- Filed
- Apr 4, 2022, 4:27 PM ET
- Trade date
- Mar 31-Apr 1, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $4.92K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Appelbaum Kevin JCIK 0001547557 | Director, Officer (Chief Executive Officer), 10% Owner |
| Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated 5/16/2020, as amendedCIK 0001890904 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 | Common Stock | PPurchaseAcquired | +2,500 | $1.97 | +$4,921.25 | 6,250 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2022 | Common Stock | AGrant or awardAcquired | +235,000 | $0.00 | $0 | 235,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.